• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 4:03:02 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SC 13G/A 1 d122146dsc13ga.htm EVOGENE LTD Evogene Ltd

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    Amendment No. 8*

    Evogene Ltd

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    M4119S104

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

    [ ] Rule 13d-1(c)

    [ ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. M4119S104                 13G

     

    1.

    NAME OF REPORTING PERSON (S.S. or I.R.S. Identification No. of Above Person)

     

        

    Ivy Investment Management Company Tax ID No. 03-0481447

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

     

      (a)

         [ ]

      (b)

         [ ]

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    5.      SOLE VOTING POWER    2,757,223 (See Item 4)
    6.      SHARED VOTING POWER    0
    7.      SOLE DISPOSITIVE POWER    2,757,223 (See Item 4)
    8.      SHARED DISPOSITIVE POWER    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

        

    2,757,223 (See Item 4)

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES:

        

    [ ]

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9: 7.8

     

    12.

    TYPE OF PERSON REPORTING: IA


    CUSIP No. M4119S104                 13G

     

    1.

    NAME OF REPORTING PERSON (S.S. or I.R.S. Identification No. of Above Person)

     

        

    Waddell & Reed Financial, Inc. Tax ID No. 51-0261715

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

     

      (a)

        [ ]

      (b)

        [ ]

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

    5.      SOLE VOTING POWER    2,757,223 (See Item 4)
    6.      SHARED VOTING POWER    0
    7.      SOLE DISPOSITIVE POWER    2,757,223 (See Item 4)
    8.      SHARED DISPOSITIVE POWER    0

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

        

    2,757,223 (See Item 4)

     

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES:

        

    [ ]

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9: 7.8

     

    12.

    TYPE OF PERSON REPORTING: HC


    Item 1(a):

    Name of Issuer: Evogene Ltd

     

    Item 1(b):

    Address of Issuer’s Principal Executive Offices:

                           13 Gad Feinstein Street, Park Rehovot P.O.B. 2100

                           Rehovot 7612002

                           Israel

     

    Item 2(a):

    Name of Person Filing:

     

      (i)

    Waddell & Reed Financial, Inc.

      (ii)

    Ivy Investment Management Company

     

    Item 2(b):

    Address of Principal Business Office:

     

      (i)-(ii):

            6300 Lamar Avenue

          

            Overland Park, KS 66202

     

    Item 2(c):

    Citizenship:

     

        

    (i), (ii): Delaware

     

    Item 2(d):

    Title of Class of Securities: Common Stock

     

    Item 2(e):

    CUSIP Number: M4119S104

     

    Item 3:

    The reporting person is:

     

      (i)

    Waddell & Reed Financial, Inc., a parent holding company in accordance with Reg. 240.13d-1(b)(1)(ii)(G);

      (ii)

    Ivy Investment Management Company, an investment advisor in accordance with Reg. 240.13d-1(b)(1)(ii)(E).


    Item 4:

    Ownership

    The securities reported on herein are beneficially owned by one or more open-end investment companies or other managed accounts which are advised or sub-advised by Ivy Investment Management Company (“IICO”), an investment advisory subsidiary of Waddell & Reed Financial, Inc. (“WDR”). The investment advisory contracts grant IICO all investment and/or voting power over securities owned by such advisory clients. The investment sub-advisory contracts grant IICO investment power over securities owned by such sub-advisory clients and, in most cases, voting power. Any investment restriction of a sub-advisory contract does not restrict investment discretion or power in a material manner. Therefore, IICO may be deemed the beneficial owner of the securities covered by this statement under Rule 13d-3 of the Securities Exchange Act of 1934 (the “1934 Act”).

    IICO and WDR are of the view that they are not acting as a “group” for purposes of Section 13(d) under the 1934 Act. Indirect “beneficial ownership” is attributed to the respective parent companies solely because of the parent companies’ control relationship to IICO.

     

      (a)

    Amount beneficially owned: 2,757,223

     

      (b)

    Percent of class: 7.8

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole voting power to vote or to direct the vote:

     

          

    WDR: 2,757,223 (indirect)

          

    IICO: 2,757,223 (direct)

     

      (ii)

    Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

     

          

    WDR: 2,757,223 (indirect)

          

    IICO: 2,757,223 (direct)

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    Item 5:

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: [ ]


    Item 6:

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of IICO, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive dividends from, as well as the proceeds from the sale of, such securities. Ivy Science & Technology Fund, a company registered under the Investment Company Act of 1940, has an interest in more than 5% of the class of securities reported herein.

     

    Item 7:

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

        

    See Attached Exhibit 2.

     

    Item 8:

    Identification and Classification of Members of the Group:

     

        

    Not Applicable.

     

    Item 9:

    Notice of Dissolution of Group:

     

        

    Not Applicable.


    Item 10:

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 12, 2021

     

    Waddell & Reed Financial, Inc.  
    By: /s/ J.J. Richie  
    Name: J.J. Richie  
    Title: Attorney-In-Fact  
    Ivy Investment Management Company  
    By: /s/ J.J. Richie  
    Name: J.J. Richie  
    Title: Attorney-In-Fact  


    EXHIBIT INDEX

     

    Exhibit
    No.
       Description
    1    Joint Filing Agreement
    2    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
    3    Power of Attorney
    Get the next $EVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Financials

    Live finance-specific insights

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Schedules Fourth Quarter 2024 Financial Results Release

      Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's

      2/20/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    SEC Filings

    See more
    • SEC Form 6-K filed by Evogene Ltd

      6-K - Evogene Ltd. (0001574565) (Filer)

      4/21/25 7:00:10 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form EFFECT filed by Evogene Ltd

      EFFECT - Evogene Ltd. (0001574565) (Filer)

      4/3/25 12:15:13 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form POS AM filed by Evogene Ltd

      POS AM - Evogene Ltd. (0001574565) (Filer)

      3/28/25 6:09:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

      Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.     The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions. Lavie

      4/21/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

      Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make

      3/6/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

      Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its l

      12/19/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors

      REHOVOT, Israel, July 12, 2023 /PRNewswire/ -- AgPlenus Ltd., an innovative company designing novel and safe crop protection products allowing food security for a rapidly growing world population, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is pleased to announce the appointment of Dr. Adrian Percy to its board of directors. Dr. Percy, who also serves as a member of Evogene Ltd.'s board of directors since March 2019, brings a wealth of expertise and a deep commitment to advancing environmentally friendly agricultural technologies. With over 25 years of experience in the agricultural industry, Dr. Adrian Percy strongly advocates for environmentally friendly agricultural and f

      7/12/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evogene Ltd

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      10/15/24 6:52:26 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G filed by Evogene Ltd

      SC 13G - Evogene Ltd. (0001574565) (Subject)

      2/14/24 8:30:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      2/11/22 12:15:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

      RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

      11/24/21 7:31:39 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Evogene with a new price target

      ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

      10/8/21 8:30:09 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

      RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

      8/23/21 11:09:14 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials